NEE

71.17

+0.86%↑

CNP.US

38.93

-0.69%↓

POR

42.33

+0.5%↑

PCYO

9.68

-0.62%↓

NEE

71.17

+0.86%↑

CNP.US

38.93

-0.69%↓

POR

42.33

+0.5%↑

PCYO

9.68

-0.62%↓

NEE

71.17

+0.86%↑

CNP.US

38.93

-0.69%↓

POR

42.33

+0.5%↑

PCYO

9.68

-0.62%↓

NEE

71.17

+0.86%↑

CNP.US

38.93

-0.69%↓

POR

42.33

+0.5%↑

PCYO

9.68

-0.62%↓

NEE

71.17

+0.86%↑

CNP.US

38.93

-0.69%↓

POR

42.33

+0.5%↑

PCYO

9.68

-0.62%↓

Search

Ormat Technologies Inc

Uždarymo kaina

SektoriusPaslaugos

85.04 -3.72

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

84.52

Max

88.33

Pagrindiniai rodikliai

By Trading Economics

Pajamos

-1.6M

41M

Pardavimai

-979K

230M

P/E

Sektoriaus vid.

42.908

22.225

Dividendų pajamingumas

0.54

Pelno marža

17.859

Darbuotojai

1,512

EBITDA

6.5M

142M

Rekomendacijos

By TipRanks

Rekomendacijos

Pirkti

12 mėnesių prognozė

+2.36% upside

Dividendai

By Dow Jones

Dividendų pajamingumas

Sektoriaus vid.

0.54%

3.68%

Kitas uždarbis

2025-08-06

Kitas dividendų mokėjimo data

2025-09-02

Kita Ex Dividend data

2025-08-19

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

-8.3B

5.4B

Ankstesnė atidarymo kaina

88.76

Ankstesnė uždarymo kaina

85.04

Naujienos nuotaikos

By Acuity

11%

89%

2 / 96 reitingas Utilities

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Strong Bearish Evidence

Ormat Technologies Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2025-08-04 21:42; UTC

Uždarbis
Įsigijimai, susijungimai, perėmimai

Cabot to Acquire Mexico Carbon Manufacturing From Bridgestone

2025-08-04 21:21; UTC

Uždarbis
Pagrindinės rinkos jėgos

Vertex Stock Falls After Pain-Drug Setback, Despite Stronger 2Q Earnings -- Update

2025-08-04 20:45; UTC

Uždarbis

Vertex Pharmaceuticals Swings to 2Q Profit as Sales Climb

2025-08-04 19:15; UTC

Pagrindinės rinkos jėgos

TransMedics Group Shares Rise on FDA Approval for Clinical Trial

2025-08-04 23:41; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2025-08-04 23:41; UTC

Rinkos pokalbiai

Nikkei May Rise on Fed Stimulus Hopes

2025-08-04 23:28; UTC

Rinkos pokalbiai

Global Equities Roundup: Market Talk

2025-08-04 23:28; UTC

Rinkos pokalbiai

Gold Seen Stuck in Range as Investors Await Fed's Next Move -- Market Talk

2025-08-04 21:30; UTC

Uždarbis

Palantir Stock Jumps. Earnings Blew Past Wall Street's Expectations. -- Barrons.com

2025-08-04 21:21; UTC

Uždarbis
Įsigijimai, susijungimai, perėmimai

Berkshire Stock Was Hammered Monday. It's Like 1999 Again. -- Barrons.com

2025-08-04 21:18; UTC

Uždarbis

Palantir Stock Jumps. Earnings Blew Past Wall Street's Expectations. -- Barrons.com

2025-08-04 20:25; UTC

Rinkos pokalbiai

India Hits Back Over Russian Oil Purchases -- Market Talk

2025-08-04 20:25; UTC

Uždarbis

Transocean 2Q Loss $938M >RIG

2025-08-04 20:25; UTC

Uždarbis

Transocean 2Q Loss/Shr $1.06 >RIG

2025-08-04 20:18; UTC

Uždarbis

Palantir Stock Jumps. Earnings Blew Past Wall Street's Stratospheric Expectations. -- Barrons.com

2025-08-04 20:15; UTC

Uždarbis

Vertex Pharma: Guidance Includes Immaterial Cost Impact From Tariffs in 2025 Based on Currently Known Tariff Rates and Regulations >VRTX

2025-08-04 20:14; UTC

Uždarbis

Vertex Pharmaceuticals Reiterated FY25 Fincl Guidance >VRTX

2025-08-04 20:14; UTC

Uždarbis

Vertex Pharma: Mark Bunnage, D.Phil., SVP of Global Research, to Assume Role of CSO Effective Feb 1, 2026 >VRTX

2025-08-04 20:14; UTC

Uždarbis

Vertex Pharma: David Altshuler, Chief Scientific Officer, Intends to Retire Aug 1, 2026 >VRTX

2025-08-04 20:13; UTC

Uždarbis

Vertex Pharmaceuticals Backs FY25 Rev $11.85B-$12B >VRTX

2025-08-04 20:09; UTC

Uždarbis

Viper Energy: Initiating Avg Daily Production Guidance for 3Q of 46,000 to 49,000 Bo/d (86,000 to 92,000 Boe/d) >VNOM

2025-08-04 20:06; UTC

Uždarbis

Palantir Earnings Blow Past Wall Street's Stratospheric Expectations -- Barrons.com

2025-08-04 20:01; UTC

Uždarbis

Vertex Pharmaceuticals 2Q Net $1.03B >VRTX

2025-08-04 20:01; UTC

Uždarbis

Vertex Pharmaceuticals 2Q Adj EPS $4.52 >VRTX

2025-08-04 20:01; UTC

Uždarbis

Vertex Pharmaceuticals 2Q Rev $2.96B >VRTX

2025-08-04 20:01; UTC

Uždarbis

Vertex Pharmaceuticals 2Q EPS $3.99 >VRTX

2025-08-04 19:41; UTC

Rinkos pokalbiai

U.S. Natural Gas Futures Settle Lower -- Market Talk

2025-08-04 19:28; UTC

Rinkos pokalbiai

U.S. Hiring Expected to Recover Once Uncertainty Dissipates -- Market Talk

2025-08-04 19:07; UTC

Rinkos pokalbiai

Oil Extends Losing Streak As OPEC+ to Raise Output -- Market Talk

2025-08-04 18:27; UTC

Rinkos pokalbiai

Gold Climbs on Rate Cut Speculation -- Market Talk

Akcijų palyginimas

Kainos pokytis

Ormat Technologies Inc Prognozė

Kainos tikslas

By TipRanks

2.36% į viršų

12 mėnesių prognozė

Vidutinis 90.8 USD  2.36%

Aukščiausias 105 USD

Žemiausias 76 USD

Remiantis 10 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Ormat Technologies Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Pirkti

10 ratings

6

Pirkti

4

Laikyti

0

Parduoti

Techninis įvertinimas

By Trading Central

12.535 / 12.705Palaikymas ir pasipriešinimas

Trumpalaikis periodas

Strong Bearish Evidence

Vidutinės trukmės periodas

Bullish Evidence

Ilgalaikis periodas

Strong Bullish Evidence

Rinkos nuotaikos

By Acuity

2 / 96 reitingas Paslaugos

Naujienos nuotaikos

Labai stiprus bulių rinkos įrodymas

Svyravimai

Žemiau vidurkio

Naujienų apimtis (RCV)

Žemiau vidurkio

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Ormat Technologies Inc

Ormat Technologies, Inc. engages in the geothermal and recovered energy power business in the United States, Indonesia, Kenya, Turkey, Chile, Guatemala, Guadeloupe, New Zealand, Honduras, and internationally. It operates in three segments: Electricity, Product, and Energy Storage. The Electricity segment develops, builds, owns, and operates geothermal, solar photovoltaic, and recovered energy-based power plants; and sells electricity. The Product segment designs, manufactures, and sells equipment for geothermal and recovered energy-based electricity generation; and provides services relating to the engineering, procurement, construction, operation, and maintenance of geothermal and recovered energy-based power plants. This segment serves contractors; and owners and operators of interstate natural gas pipelines, gas processing plants, and cement plants, as well as companies in other energy-intensive industrial processes. The Energy Storage segment offers battery energy storage systems and related services. Ormat Technologies, Inc. was founded in 1965 and is headquartered in Reno, Nevada.